Literature DB >> 34251648

SIRT1 Protects Dopaminergic Neurons in Parkinson's Disease Models via PGC-1α-Mediated Mitochondrial Biogenesis.

Yu Chen1, Yuhui Jiang2, Yinuo Yang2, Xinzhong Huang3, Cheng Sun4,5.   

Abstract

SIRT1 is a deacetylase with multiple physiological functions by targeting histones and non-histone proteins. It has been shown that SIRT1 activation is involved in neuroprotection in Parkinson's disease (PD) models. In the present study, we provided direct evidences showing the neuroprotective roles of SIRT1 in dopaminergic neurons. Our data showed that increased expression of SIRT1 plays beneficial roles against MPP+ insults in SH-SY5Y cells and primary dopaminergic neurons, including increased cell viability, reduced LDH release, improved the mitochondrial membrane potential (MMP), and attenuated cell apoptosis. On the contrary, knockdown of SIRT1 further aggravated cell injuries induced by MPP+. Moreover, mutated SIRT1 without deacetylase activity (SIRT1 H363Y) failed to protect dopaminergic neurons from MPP+ injuries. Mechanistically, SIRT1 improved PGC-1α expression and mitochondrial biogenesis. Knockdown of PGC-1α almost completely abolished the neuroprotective roles of SIRT1 in SH-SY5Y cells. Collectively, our data indicate that SIRT1 has neuroprotective roles in dopaminergic neurons, which is dependent upon PGC-1α-mediated mitochondrial biogenesis. These findings suggest that SIRT1 may hold great therapeutic potentials for treating dopaminergic neuron loss associated disorders such as PD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Dopaminergic neurons; Mitochondrial biogenesis; PGC-1α; Parkinson’s disease; SIRT1

Mesh:

Substances:

Year:  2021        PMID: 34251648     DOI: 10.1007/s12640-021-00392-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  1 in total

1.  Mir-141-3p Regulates Apoptosis and Mitochondrial Membrane Potential via Targeting Sirtuin1 in a 1-Methyl-4-Phenylpyridinium in vitro Model of Parkinson's Disease.

Authors:  Yumin Zheng; Li Dong; Na Liu; Xiaoguang Luo; Zhiyi He
Journal:  Biomed Res Int       Date:  2020-11-06       Impact factor: 3.411

  1 in total
  4 in total

Review 1.  Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases.

Authors:  Danial Khayatan; Seyed Mehrad Razavi; Zahra Najafi Arab; Maryam Khanahmadi; Saeideh Momtaz; Alexandra E Butler; Fabrizio Montecucco; Yuliya V Markina; Amir Hossein Abdolghaffari; Amirhossein Sahebkar
Journal:  Life (Basel)       Date:  2022-05-20

Review 2.  Histone Deacetylases as Epigenetic Targets for Treating Parkinson's Disease.

Authors:  Yan Li; Zhicheng Gu; Shuxian Lin; Lei Chen; Valentina Dzreyan; Moez Eid; Svetlana Demyanenko; Bin He
Journal:  Brain Sci       Date:  2022-05-21

Review 3.  Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson's Disease.

Authors:  Jannik Prasuhn; Norbert Brüggemann
Journal:  Genes (Basel)       Date:  2021-11-22       Impact factor: 4.096

Review 4.  Sirtuins and cognition: implications for learning and memory in neurological disorders.

Authors:  Eric Fagerli; Iris Escobar; Fernando J Ferrier; Charles W Jackson; Efrain J Perez-Lao; Miguel A Perez-Pinzon
Journal:  Front Physiol       Date:  2022-07-22       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.